82 related articles for article (PubMed ID: 10769703)
1. Response of MHC class-1 antigen on rat glioma cells to cytokines.
Oshiro S; Fukushima T; Tomonaga M; Black KL
Anticancer Res; 2000; 20(1C):605-10. PubMed ID: 10769703
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and modified immunoregulation associated with IFN-gamma treatment of RG2 gliomas.
Oshiro S; Fukushima T; Tomonaga M; Black KL
Anticancer Res; 1999; 19(6B):5029-36. PubMed ID: 10697506
[TBL] [Abstract][Full Text] [Related]
3. Modified immunoregulation associated with interferon-gamma treatment of rat glioma.
Oshiro S; Liu Y; Fukushima T; Asotra K; Black KL
Neurol Res; 2001 Jun; 23(4):359-66. PubMed ID: 11428516
[TBL] [Abstract][Full Text] [Related]
4. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
5. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
6. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
7. Impaired capacity for upregulation of MHC class II in tumor-associated microglia.
Schartner JM; Hagar AR; Van Handel M; Zhang L; Nadkarni N; Badie B
Glia; 2005 Sep; 51(4):279-85. PubMed ID: 15818597
[TBL] [Abstract][Full Text] [Related]
8. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
9. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
10. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
11. Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells.
De Vleeschouwer S; Arredouani M; Adé M; Cadot P; Vermassen E; Ceuppens JL; Van Gool SW
Cancer Immunol Immunother; 2005 Apr; 54(4):372-82. PubMed ID: 15692847
[TBL] [Abstract][Full Text] [Related]
12. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma.
Kobayashi T; Yamanaka R; Homma J; Tsuchiya N; Yajima N; Yoshida S; Tanaka R
Cancer Immunol Immunother; 2003 Oct; 52(10):632-7. PubMed ID: 12827308
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
[TBL] [Abstract][Full Text] [Related]
14. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
15. B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity.
Paul DB; Barth RF; Yang W; Shen GH; Kim J; Triozzi PL
Gene Ther; 2000 Jun; 7(12):993-9. PubMed ID: 10871746
[TBL] [Abstract][Full Text] [Related]
16. Immunological profiling of a panel of human ovarian cancer cell lines.
Carr TM; Adair SJ; Fink MJ; Hogan KT
Cancer Immunol Immunother; 2008 Jan; 57(1):31-42. PubMed ID: 17579858
[TBL] [Abstract][Full Text] [Related]
17. [Influence of adjustment of balance of Th1/Th2 type cytokines on proliferation of glioma cells].
Hu YS; Zhang QL; Tian ZG; Wei HM; Zhang JH; Li G; Pang Q; Wang CW; Jin P; Sun R
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):599-602. PubMed ID: 12901106
[TBL] [Abstract][Full Text] [Related]
18. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
19. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.
Hussain SF; Yang D; Suki D; Aldape K; Grimm E; Heimberger AB
Neuro Oncol; 2006 Jul; 8(3):261-79. PubMed ID: 16775224
[TBL] [Abstract][Full Text] [Related]
20. Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1.
Usui Y; Okunuki Y; Hattori T; Takeuchi M; Kezuka T; Goto H; Usui M
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4607-13. PubMed ID: 17003458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
